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http://www.biomedcentral.com/1471-2172/15/46RESEARCH ARTICLE Open AccessC-Jun N-terminal kinase (JNK) isoforms play
differing roles in otitis media
William Yao1,2, Meredith Frie1,2, Jeffrey Pan1,2, Kwang Pak2,3, Nicholas Webster4, Stephen I Wasserman5
and Allen F Ryan2,3,6*Abstract
Background: Innate immunity and tissue proliferation play important roles in otitis media (OM), the most common
disease of childhood. CJUN terminal kinase (JNK) is potentially involved in both processes.
Results: Genes involved in both innate immune and growth factor activation of JNK are upregulated during OM,
while expression of both positive and negative JNK regulatory genes is altered. When compared to wildtypes (WTs),
C57BL/6 mice deficient in JNK1 exhibit enhanced mucosal thickening, with delayed recovery, enhanced neutrophil
recruitment early in OM, and delayed bacterial clearance. In contrast, JNK2−/− mice exhibit delayed mucosal
hyperplasia that eventually exceeds that of WTs and is slow to recover, delayed recruitment of neutrophils, and
failure of bacterial clearance.
Conclusions: The results suggest that JNK1 and JNK2 play primarily opposing roles in mucosal hyperplasia and
neutrophil recruitment early in OM. However, both isoforms are required for the normal resolution of middle ear
infection.
Keywords: Middle ear, Nontypeable haemophilus influenzae, Infection, MAP kinase signaling, Tissue proliferation,
InflammationBackground
Otitis media (OM) is one of the most prevalent and
costly acute medical problems that afflict children and
infants aging from six months to six years [1-3]. Al-
though acute OM may not cause immediate concern in
developed countries, persistent and chronic OM pro-
duces a sustained conductive hearing loss and may result
in irreversible damage to the middle and/or inner ear. In
the developing world, in contrast, OM causes an esti-
mated 30,000 deaths per year, and contributes to half of
the world’s burden of serious hearing loss [4]. Under-
standing the pathogenesis of OM is thus an important
research goal.
Consequences of OM to the middle ear (ME) include
hyperplasia of the ME mucosa with the potential for
mucus secretion, leukocytic infiltration into the ME* Correspondence: afryan@ucsd.edu
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unless otherwise stated.cavity, and ME effusion; ME inflammation associated with
OM can also cause tissue damage and intense pain. While
OM is multifactorial, one of its most prominent causes is
bacterial infection. In particular, as the usage of pneumo-
coccal vaccines has increased, the incidence of OM caused
by nontypeable Haemophilus influenzae (NTHi) has risen
[5]. The mechanisms by which bacteria influence the ME
during OM is a subject of increasing interest. With respect
to the context of the present study, there is extensive evi-
dence that innate immune receptors play a role in the
resolution of acute OM e.g. [6], but the downstream effec-
tors of pathogen-induced responses in the ME are not well
understood. Both the Toll-like receptor (TLR) and NOD-
like receptor families of innate immune receptors can
signal via CJUN N-terminal kinase (JNK) to activate proin-
flammatory target gene expression including cytokines and
chemokines. However, JNK is also the product of a proto-
oncogene, and like other mitogen activated protein kinases
(MAPKs) [7] can be a potent mediator of tissue growth
[8]. Finally, JNK is a stress protein and has been shown to
mediate apoptosis in some circumstances [9].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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OM would not only improve our understanding of ME
immune signaling and its regulation, but might also pro-
vide new gene targets for alternative OM treatments.
JNK signaling is complex, with numerous upstream and
downstream molecules potentially participating. TLR
signaling via JNK involves the TLR adaptor MyD88,
which activates IRAK4 and TRAF6, in turn activating
TAK1. TAK1 phosphorylates the MAP kinase kinases
(MAP2Ks) 4 and 7, which in turn activate JNK [10]. Ac-
tivated JNK phosphorylates members of the JUN family
of proteins, including CJUN, JUNB, JUND, as well as
ATF2. Phosphorylated CJUN homodimerizes or forms
heterdimers with phosphorylated FOS or ATF2, to form
the AP-1 transcriptional activator, which can potentially
regulate many genes [11,12]. Growth factor binding to
their cognate receptors recruit adaptors, including SHC,
GRB and SOS, can activate the small GTPases KRAS,
and CDC42 [13], which in turn activate MAPK kinase
kinase kinases (MAP3Ks) 1 and 4. These converge with
TLR signaling by activating MAP2Ks 4 and 7 to, in turn,
phosphorylate JNK.
Activation of the JNK pathway is also regulated by
multiple scaffolding proteins, which function to collect
signaling effectors into molecular complexes to regulate
signal transduction and localize the complexes to spe-
cific parts of the cell. These include the JNK-interacting
proteins (JIPs) 1–3, which can aggregate MLK, MAPKs
2 and 7, and JNK to enhance JNK activation. Similarly,
POSH (plenty of SH3) interacts with MLK3 to aid in
JNK phosphorylation [14] while arrestin β2 (ARRB2) has
been shown to dock directly to MAP2K4 [15] and acti-
vate JNK [16]. The dual specificity phosphatase (DUSP)
proteins are scaffolds that influence MAPKs with varying
actions and specificity [17]. DUSP1, 2, 8 and 10 posi-
tively regulate JNK. DUSP 16 [18], 18, 19 (SKRP1) and
22 inhibit JNK activity [19,20]. CDC42EP2 can also in-
hibit JNK by blocking the activity of upstream CDC42
[21], while the JNK target CJUN can be inhibited by
competition with JUNB.
JNK signaling is complicated by the fact that JNK is
not one protein. Three JNK genes (Jnk1, Jnk2, Jnk3)
can be alternatively spliced into 10 isoforms, which
allows for different JNK activities in specific tissue
types [22]. The Jnk1 and Jnk2 genes are expressed in
tissues throughout the body, but Jnk3 has expression
limited primarily to the brain, heart and testes [7].
JNK1 and JNK2 have been implicated as important in
immune signaling and evidence has shown that JNK1
and JNK2 protein activation is increased in rat ME
mucosa during OM [23].
The JNK1 and JNK2 isoforms have been shown to per-
form different signaling roles to induce specific physio-
logical changes [22]. However, differences between JNK1and JNK2 actions are not well characterized, and most
JNK effectors are stimulated by both JNK1 and JNK2,
making it difficult to determine signaling differences
between the two molecules.
The objective of this study was to investigate JNK signal-
ing networks during OM, by documenting the expression
of various genes in the JNK signaling cascade during the
course of a ME infection, and by comparing OM in mice
deficient in JNK1 or JNK2 with that in wildtype (WT)
mice. We hypothesized that genes encoding many ele-
ments of JNK signaling pathways would be regulated
during OM, and that JNK1 and JNK2 would contribute
to different aspects of the OM phenotype.
Methods
Animals
Experimental methods and protocols were performed on
healthy, naive 60–90 day old (~25 gm) mice, according
to the National Institutes of Health guidelines on the
care and use of laboratory animals and approved by the
Institutional Animal Care and Use Committee of the
San Diego VA Medical Center. Mice were used since
acute OM in this species is quite similar to the disease
in humans [3,24], and since gene knockouts are avail-
able. Animals were housed under SPF conditions with
4–6 mice per cage, free access to food and water, and
environmental enrichment. Gene array studies were per-
formed on C57/CB F1 hybrid mice (Jackson Labs, Bar
Harbor, ME), to reduce the influence of the recessive
mutations common in inbred mouse strains. Knockout
experiments were performed on mice systemically defi-
cient in JNK1 or JNK2 on a C57BL/6 background, and
upon C57BL/6 WT controls (bred in-house from
Jackson Labs stock), since they were produced on this
background. Gene deficient animals are most frequently
created in this species/strain. Generating C57/CB F1
hybrids with the KOs would not have been possible. It
should be noted that we have performed arrays on
C57BL/6 mice at 6 and 48 hours after NTHi inoculation,
and the results are quite similar to those seen with C57/
CB F1 hybrid mice.
Bacterial strain and culture conditions
Minimally passaged Haemophilus influenzae strain 3655
(nontypeable, biotype II; extracted from the ME of a
child with OM) was grown, inoculated, and used at a
concentration of 105 -106 bacteria/ml to generate an
inflammatory response within the ME. Inocula were
prepared as described by Melhus and Ryan [3].
Surgical procedure
Surgeries were performed aseptically in a designated
area of the laboratory. WT, JNK1−/−, and JNK2−/− mice
were anesthetized with an intraperitoneal injection of
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(13.3 mg/ml ketamine HCL, 1.3 mg/ml xylazine and
0.25 mg/ml acepromazine), which provides brief, deep
anesthesia. MEs were exposed bilaterally by a ventral ap-
proach through a midline neck incision. ME bullae were
then punctured using a 25-gauge needle. Approximately 5
microliters of NTHi (500–5000 cfu at 105 -106 bacteria/ml)
were injected into the ME cavity using a 30-gauge needle,
which allowed air to exit the ME opening during injection.
Excess fluid was soaked up with a sterile cotton swab. The
wound was closed and the skin incision was stapled. The
mice were injected with the analgesic buprenorphine and
lactated Ringer’s solution subcutaneously. Mice were exam-
ined for fluid leakage into the external ear canal to ensure
no penetration of the tympanic membrane had occurred
from the 25-gauge needle. Surgeries were timed to permit
sacrifice at the appropriate interval. All animals were moni-
tored after surgery until ambulatory, and then daily for
health status until sacrifice. No adverse events occurred.
DNA microarray
Expression of genes involved in JNK signaling was evalu-
ated during the course of an acute episode of OM in
WT mice by DNA microarray. For each time point eval-
uated, twenty WT mice were inoculated with NTHi as
above. The ME mucosae were harvested at each of the
following intervals: 0, 3 and 6 hours, as well as 1, 2, 3, 5
and 7 days after NTHi inoculation. 0 hour (control)
mice received no treatment. The tissue was homoge-
nized in TRIzol™ (Invitrogen, Carlsbad, CA) and total
RNA was extracted. RNA was labeled and hybridized to
two Affymetrix MU430 2.0 microarrays. This procedure
was then duplicated with an additional 20 mice for each
time point, to obtain an independent replication. Gene
transcript expression levels were evaluated using variance-
modeled posterior inference (VAMPIRE) [25]. Functional
gene families were assessed by gene ontogeny (GO) ana-
lysis, and specific genes were assessed at individual time
points, after Bonferonni correction for multiple tests, using
Genespring GX 7.3 (Agilent). Individual gene behavior was
evaluated as fold change from expression observed in
uninoculated (0 hour) control mice.
As a control, mock injection of only saline was per-
formed in identical groups of mice. This also resulted in
the significant regulation of some genes. However, they
almost invariably exhibited lower levels of regulation
than that seen after NTHi inoculation. For the 47 genes
reported here, 30 were not regulated by saline injection,
and all of the remaining genes were regulated at lower
levels, many substantially so (data not shown).
Histology
OM was evaluated in 3 experimental groups: 33 JNK1−/−
mice, 33 JNK2−/− mice, and 33 WT control mice withthe same genetic background (C57BL/6). JNK knockout
and C57BL/6 strains were obtained from Jackson Labs.
Each of these groups was randomly subdivided into sets of
3 mice, 1 set for each of 11 time points. When more than
one batch of bacteria was used each batch was distributed
between all groups. The mice were bilaterally inoculated in
the ME with NTHi, and were sacrificed under general
anesthesia by intracardiac perfusion with 3 ml of PBS
followed by 3 ml of a 4% paraformaldehyde solution at 0, 6
or 12 hrs or 1, 2, 3, 5, 7, 10,14, or 21 days after inoculation.
In all experiments, the 0 hr time point represents un-
treated MEs. The MEs were extracted, postfixed with 4%
PFA overnight, and decalcified in an 8% EDTA/4% PFA
solution over a 14 day period. The ME bullae were
embedded in paraffin and serially sectioned at 7 microme-
ters. Sections were stained with hematoxylin-eosin and
mounted. Images of the ME cavity were digitally recorded
and mucosal thickness and percentage area of the ME
lumen that contained inflammatory cells were determined
from standardized areas spaced throughout the ME, using
6 MEs per condition, as described previously [26].
To identify the cells present in the ME, high-
magnification (400×) images were captured for regions
with inflammatory cells in the lumen. The number of
neutrophils and macrophages present in each 400×
image was counted, and counts from 3 images were av-
eraged for each ME. Data from 6 MEs were evaluated
per condition.
Bacterial clearance
The presence of live bacteria in the ME was evaluated in
3 experimental groups: 21 JNK1−/− mice, 21 JNK2−/−
mice, and 21 WT control mice (C57BL/6). Each group
was randomly subdivided into sets of 3 mice, 1 for each
of 7 time points. MEs were extracted from 3 WT and 3
JNK knockouts for each isoform (JNK1 or JNK2) at 1, 2,
3, 5, 10, 14, and 21 days after ME inoculation. The MEs
were opened and a 1-microliter loop was used to obtain
a sample from the ME lumen for NTHi culture onto
chocolate agar plates with nutrients specific for NTHi
growth. For MEs without fluid present, the loop was
rubbed across the ME mucosal surface. Each loop was
T-streaked onto 4 successive quadrants of each plate.
The plates were then analyzed after 24 hours’ incubation
at 37°C. The identity of NTHi was verified by plate
specificity and by colony color and morphology.
Bacterial data were analyzed by determining the pres-
ence or absence of NTHi in each plate, and quantified
by counting the number of quadrants in which colonies
were observed.
Statistical analysis
Data were analyzed using Statview (Scientific Computing,
Cary, NC). Parametric data were analyzed by ANOVA with
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comparisons, for tests of individual time points.
Leukocyte counts were measured as percentages, and
these data were analyzed with the Kruskal-Wallace
nonparametric ANOVA equivalent, and the Mann–
Whitney U test for individual time point analysis. All
animals in each group were included in the analyses,
and no animals were excluded.
Results
Expression of JNK signaling genes in the ME during OM
The expression of mRNA transcripts encoding elements
of the innate immune and growth factor JNK signaling
cascades leading to the activation of JNK were evaluated
from ME gene array data generated before and during
NTHi-induced OM. As illustrated in Figures 1, 2, 3 and
Additional file 1: Table S1, genes encoding many of the
elements of JNK signaling were differentially regulated
during OM. Figure 1 illustrates the fold changes ob-
served for genes that link innate immune receptors to
JNK. In general, gene regulation was moderate and long-
lasting. Just downstream from the receptor complex,
Traf6 and Irak4 exhibited peaks on enhanced expression
at 6 and 24 hours after inoculation, while Tak1 exhibited
more sustained up-regulation. Jnk1 and Jnk2 were mod-
estly enhanced during ME infection. Jnk3 was not only
expressed at much lower initial levels than the other iso-
forms, but was consistently down-regulated during OM.
However, the gene encoding the direct JNK phosphoryl-
ation target Cjun was rapidly, vigorously, and persistently
up-regulated.Figure 1 Regulation of JNK signaling genes during OM. ME expression
assessed by DNA microarray. Genes involved in TLR JNK signaling.Figure 2 documents the regulation of many of the genes
that participate in growth factor activation of JNK. Most of
the significantly affected genes were up-regulated, and
most peaked at 24 hours after inoculation. Exceptions were
Cdc42, the most highly up-regulated gene, which peaked
at 6 hours, and Map3K1 and Map3K4, which were down-
regulated in the first hours after NTHi inoculation, but
then recovered to pre-inoculation levels.
Figure 3 illustrates the regulation of genes that modulate
the JNK signaling pathway. All of the significantly affected
positive regulators were up-regulated, most within 3 hours
of inoculation. The negative regulators were more variable.
Junb was strongly up-regulated at 3 hours and remained
elevated until 2 days, while Dusp16 peaked at 1 day.
Dusp18 was strongly down-regulated at 6 hours, while
Dusp19 was slightly up-regulated at 2 days.
While CJUN is the canonical phosphorylation target of
the JNKs, many additional targets have been identified,
including other potential components of the AP-1 tran-
scriptional complex such as JUNB, JUND, and ATF2,
growth regulators and apoptosis-related proteins. The
expression of 38 genes encoding JNK phosphorylation
targets was assessed during OM (see Additional file 2:
Table S2), 18 that are activated by JNK phosphorylation,
18 that are inhibited, and 2 that can be dually affected
[27]. Of these, 14 activation genes, 9 inhibition genes
and both dual genes were regulated. Up-regulation was
most common (20 of 25 genes), but down-regulated
genes included the growth suppressor p53 (an activation
target) and the apoptosis suppressor Bcl2 (potentially
dually affected).of genes related to the JNK signaling pathway in WT mice during OM,
Figure 2 Regulation of JNK signaling genes during OM. ME expression of genes related to the JNK signaling pathway in WT mice during OM,
assessed by DNA microarray. Genes invoved in growth factor JNK signaling.
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clearance of NTHi infection
WT mice inoculated in the ME with NTHi exhibited posi-
tive cultures at 1d, 2d and 3d, with 6/6 MEs being positive
in multiple quadrants at 2d. The degree of bacterialFigure 3 Regulation of JNK signaling genes during OM. ME expression
assessed by DNA microarray. Genes involved in JNK signaling regulation. Th
infection. Jnk1 was up-regulated for the first few days of OM, while Jnk2 ex
up-regulation on subsequent days. In contrast, many of the genes up- and
activator genes Cdc42, Rac2 and Arrb2, and the down-stream target genes
Cdc42ep2 were rapidly and persistently up-regulated. *P <0.05, **P <0.01, *recovery declined regularly from d1 to d3. No NTHi
colonies were cultured from WT mice on d5 and there-
after. In contrast, the clearance of bacteria from JNK-
deficient mice was greatly delayed. In the case of JNK1−/−
mice, 4/6 MEs were positive for bacteria on d5, a lowof genes related to the JNK signaling pathway in WT mice during OM,
e genes encoding JNK1 and JNK2 were modestly regulated by NTHi
hibited down-regulation 3–6 hours after inoculation, followed by
down-stream of JNK were strongly regulated. The up-stream JNK
cJun, Stat3 and Stat4, and the negative regulator genes Dusp16 and
**P <0.001, compared to 0 hour expression.
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and clearance was not achieved until 21d. In JNK2−/− mice,
NTHi were isolated from at least some MEs at all times,
including at 21d, and the degree of bacterial colonization
at later times was greater than for JNK1−/− mice (Table 1).
Histology of the ME during OM
Figure 4 illustrates the mucosal response of WT and
JNK-deficient mice to NTHi inoculation of the ME. The
ME of WT mice exhibit a characteristic inflammatory
response when infected with NTHi [3,24,28,29]. The epi-
thelial and stromal layers of the mucosa increase in
thickness, and influxes of neutrophils and macrophages
successively enter the ME cavity. In WT mice, these re-
sponses peak at d1-3 after inoculation with NTHi, and
the ME returns to its pre-inoculation condition after
7–10 days. In both JNK1−/− and JNK2−/− mice, the ME
undergoes mucosal thickening and infiltration of inflam-
matory cells, with the changes most prominent at d2
after inoculation. However, in JNK1−/− mice the ME
failed to return to a pre-inoculation condition until after
10 days. It was also observed that a subset of JNK2−/−
mice underwent resurgence of inflammation at d7, but
also returned to normal by d10.
Mucosal thickness
One measure of inflammation in the ME is the thickness
of the mucosa, which displays hyperplasia in response to
various inflammatory stimuli [24,29]. Quantitative data
on the thickness of the ME mucosal epithelium and
stroma are presented in Figures 5, 6, 7. In WT mice,
modest growth of the mucosal epithelium (Figure 6) and
more substantial expansion of the stroma (Figure 7) was
apparent by 1d after NTHi infection. Both epithelial and
stromal growth peaked at 2d and recovered baseline
levels by 3-5d. In JNK1−/− mice, the mucosal epithelium
exhibited significant overproliferation at 1d, 2d, 3d, 5d
and 7d (p ≤ .05). The stroma exhibited greater growth at
3d, 5d, and 7d (p ≤ .05). JNK2−/− mice initially exhibitedTable 1 Bacterial clearance
Time after
NTHi inoculation
WT #
of culture
positive plates
WT
Quadrants
positive in culture
positive plates
JNK1−/−
# of cultur
positive pl
Day 1 4/6 4.00 5/6
Day 2 6/6 3.00 2/6
Day 3 3/6 1.00 4/6
Day 5 0/6 0.00 4/6
Day 10 0/6 0.00 3/6
Day 14 0/6 0.00 2/6
Day 21 0/6 0.00 0/6
No NTHi colonies were isolated from the ME for WT mice, from 5 days after infectio
NTHi was isolated throughout the 21 day observation period.delayed growth of both the epithelium and stroma com-
pared to WT mice, with significantly lower thickness at
1d (p < .05). Subsequently, the mucosal epithelium was
thicker than in WT mice at 3d, 5d and 7d (p ≤ .05). The
stromal compartment showed significant over prolifera-
tion at 2d, 3d and 7d (p ≤ .05). Interestingly, the epithe-
lium and stroma of JNK2−/− mice became slightly but
significantly less thick than the WT at 10d (p ≤ .05).
Leukocyte infiltration of the ME
In WT mice, the percentage of ME cavity occupied by in-
flammatory cells peaked at 2d and had recovered to base-
line levels by 7d (Figure 7). When infiltrating cells were
further quantified as to cell type, WT mice showed neutro-
phil infiltration to the ME cavity beginning at 6 h, peaking
at 1d, and returning to baseline levels by 5d (Figure 8).
Macrophage infiltration in WTs peaked at 2d and returned
to baseline levels by 7d (Figure 9).
In JNK1−/− mice, the percentage of the ME occupied by
inflammatory cells was similar to that observed in WTs,
with the exception that a somewhat lower proportion of
cells was seen at 5d (p ≤ .01) (Figure 7). When cell infiltra-
tion was evaluated for cell type, JNK1−/− neutrophil infil-
tration slightly but significantly exceeded that seen in WTs
at 6 h (p ≤ .05), was dramatically higher at 1d and modestly
higher at 7d (p ≤ .01) (Figure 8).
JNK2−/− mice showed substantially greater inflamma-
tory cell infiltration into the ME cavity at 2d and 7d
(p ≤ .05), and a slight but significant decrease at 6 h
(Figure 7). JNK2−/− neutrophil infiltration was significantly
increased at 7d (p ≤ .01) (Figure 8), while macrophage
infiltration was dramatically increased at 2d (p ≤ .01)
(Figure 9).
Discussion
Regulation of JNK signaling genes supports a role in the
host response to ME infection
As seen in the microarray data for the ME mucosa,
many of the genes that are involved in the JNK pathwaye
ates
JNK1−/−
Quadrants positive
in culture positive
plates
JNK2−/−
# of culture
positive plates
JNK2−/−
Quadrants positive
in culture positive
plates
3.20 3/6 2.33
3.00 4/6 2.75
2.50 5/6 2.80
2.00 2/6 1.50
1.00 1/6 4.00
1.00 1/6 1.00
0.00 2/6 2.50
n onward. In JNK1−/− mice, NTHi were isolated up to day 14. In JNK2−/− mice,
Figure 5 ME mucosal hyperplasia. Evaluation of thickness of the
ME mucosal epithelium of WT (filled circles), JNK1−/− (open circles)
and JNK2−/− (gray squares) mice after NTHi inoculation.
Figure 6 ME mucosal hyperplasia. Thickness of the ME
subepithelial stroma. A significant delay in epithelial and stromal
growth is observed for JNK2−/− mice, while prolonged thickness was
seen in both mutant strains. Thickness was assessed at standardized
locations in the ME and averaged for each animal, and then across
animals for each post-inoculation time. (* = p < .05; ** = p < .01,
comparing KOs to WTs).
Figure 4 Middle ear histology. Representative micrographs of the
ME mucosal response to nontypeable Haemophilus influenzae (NTHi)
in C57BL/6 (WT) mice, JNK1−/− mice, and JNK2−/− mice. Prior to
infection (0d), the MEs of WT mice have a thin, simple mucosal layer
consisting of a simple, squamous epithelium and minimal stroma. In
contrast, 1–2 days after infection, the mucosa significantly thickens
due to expansion of the stroma and hyperplasia of the mucosa into
a columnar form. From 3–5 days, the WT mucosa essentially returns
to baseline condition. Prior to infection, the JNK1−/− ME also exhibits
a simple mucosa, which thickens considerably in the initial days after
infection. However, the mucosa remains substantially hyperplasic
through 7 days after infection. Prior to infection, JNK2−/− MEs also
have a normal-appearing mucosa, and similar to JNK1−/− mice exhibit
prolonged hyperplasia. However, JNK2−/− mice displayed a second peak
of hyperplasia 7 days after infection, prior to recovering to normal
thickness by 10–14 days. Bar =50 μm.
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This degree of regulation suggests that the pathway plays
a critical role in this condition. It is significant that the
up-regulation of most genes peaked at 1d after inocula-
tion. ME inflammation, leukocytic infiltration and muco-
sal hyperplasia all peaked at 2d after inoculation. Given
the delays to be expected in protein synthesis and cellu-
lar responses, the increase in gene expression related to
JNK signaling is well positioned to participate in all
three manifestations of OM.
It should be noted that we observed only modest regula-
tion of the genes encoding JNK1 and JNK2 themselves.
This suggests that these signaling molecules are main-
tained at functional levels in the resting ME, and are pre-
dominantly regulated post-transcriptionally, perhaps by
phosphorylative activation. This is consistent with prior
data at the protein level demonstrating little change in
total JNK during OM, but increased phospho-JNK1 and-JNK2 [23]. In contrast, the genes encoding signaling mol-
ecules upstream from JNK (e.g. IRAK4, CDC42, KRAS)
were up-regulated during OM, suggesting increased in-
volvement of JNK signaling during the course of OM.
Again, protein data confirms a peak of phospho-JNK at
72 h after initiation of infection [23]. We also found that
genes encoding both positive (e.g. ARRB2, RAC2) and
negative (e.g. CDC42EP2, DUSP16) regulators of the JNK
pathway showed significant up-regulation during OM, sug-
gesting tight regulation of JNK activity, perhaps to prevent
bystander injury to host tissues from inflammation and/or
apoptosis [30].
Figure 9 Cellular infiltration of the ME cavity. The number of
macrophages present in areas of cellular infiltration, determined
from the same images. Cell values were averaged across animals for
each post-inoculation time. (* = p < .05; ** = p < .01, comparing KOs
to WTs).
Figure 7 Cellular infiltration of the ME cavity. Percent area of the
ME cavity occupied by leukocytes. Since the position of effusion in
the ME is variable, the area occupied by cells was computed for the
region of each ME that exhibited the maximum cellular effusion.
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JNK, CJUN, showed very strong and early up-
regulation. CJUN dimerizes with members of the JUN,
FOS or ATF2 subfamilies to create AP-1 [31], a multi-
functional transcription factor. AP-1 induces the
production of multiple pro-inflammatory cytokines, in-
cluding tumor necrosis factor alpha (TNFA) [32].
TNFA is a proinflammatory mediator important in in-
nate immunity. It is strongly expressed during OM and
TNFA−/− mice have shown delayed NTHi-induced OM
resolution [28]. This suggests that the JNK pathway is
critical in inducing inflammation, which in turn is crit-
ical for proper recruitment and access of immune cells
to the site of infection for infection clearance. This isFigure 8 Cellular infiltration of the ME cavity. The number of
neutrophils present in areas of cellular infiltration. A high-power
(400×) field centered on the area of highest cell infiltration was
imaged, and the number of neutrophils in the field was quantified.consistent with the delayed bacterial clearance ob-
served in both JNK1- and JNK2-deficient mice. AP-1 is
also implicated in tissue proliferation [33]. Its primary
components, CJUN and CFOS, are both positive regu-
lators of tissue growth and their active heterodimers
can cause anchorage-independent proliferation [34].
The up-regulation of GF-related JNK signaling genes is
consistent with a role for JNK in tissue proliferation
during OM. The regulation of a majority of genes en-
coding direct JNK phosphorylation targets involved in
AP-1 transcription, tissue proliferation and apoptosis
[11,35,36] further implicates the molecules of the JNK
signaling system in OM.
JNK deletion indicates that both isoforms play a role in OM
Both JNK1−/− and JNK2−/− mice showed significantly
different physiological responses to NTHi infection of
the ME when compared to WT animals. Both mutants
exhibited delayed bacterial clearance, as well as atypical
leukocyte recruitment. Both JNK1−/− and JNK2−/− also
showed a delayed return to baseline mucosal thickness.
Interestingly, both JNK1−/− and JNK2−/− MEs showed
evidence of a resurgence of OM at 7d, after the initiation
of recovery. The similarity of these changes suggests that
JNK1 and JNK2 are both necessary for a normal innate
immune response to OM, and that some functions of
the two isoforms appear to overlap.
Albeit delayed, eventual resolution of infection was ob-
served in all JNK1−/− mice and in most JNK2−/− mice.
Moreover, the basic histopathologic features of OM,
although altered, were present in both strains, and
both mutants showed return of mucosal thickness and
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between the two isoforms and/or JNK-independent
mechanisms that operate in parallel with JNK-
dependent processes to mediate pathogenesis and re-
covery from OM. NFκB, known to mediate innate
immune responses in addition to JNK, is a strong can-
didate for such a parallel pathway [37].
We did not obtain evidence that an individual JNK
isoform is responsible for hyperplasia of the ME mucosa,
since neither JNK1- nor JNK2-deficient animals exhibited
a consistently decreased proliferative response to bacterial
infection. Rather, the proliferative response was more
persistent, presumably reflecting prolonged bacterial in-
fection. Since we have previously shown that a pan-JNK
inhibitor reduces mucosal proliferation during OM [23],
our current results suggest redundancy between the two
isoforms. Of course, JNK-independent pathways may also
be involved. Growth factor stimulation can activate alter-
native growth pathways mediated by the extracellular
signal-regulated kinases (ERK) and p38 MAP kinases,
both of which have been shown to be activated during
OM [38,39], and as above NFκB is another potential
contributory pathway.
JNK1 and JNK2 have distinct roles in regulating the ME
response to NTHi
Although the mechanistic differences remain unclear, it is
known that JNK1 and JNK2 are not necessarily inter-
changeable in the JNK signaling pathway. This is also ap-
parent in our data, since the two isoforms were unable to
completely compensate for each other during OM and
since the ME phenotypes of the two mutants were distinct.
JNK1-deficient mice exhibited earlier growth of the muco-
sal epithelium compared to the WT. In contrast, JNK2−/−
mice exhibited a delay in the growth of both the mucosal
epithelium and stroma. JNK1−/− mice exhibited greatly en-
hanced neutrophil recruitment early in OM, while JNK2-
deficient mice exhibited a delay in neutrophil recruitment
and greater persistence of neutrophils. JNK2−/− mice also
showed enhanced macrophage recruitment to the ME,
while JNK1−/− mice did not. The phenotype of JNK2−/−
mice suggests a more serious defect in inflammation than
seen in JNK1−/− mice, given the delays in mucosal prolifer-
ation and leukocyte recruitment and the greater persist-
ence of bacterial infection in these mice. This may reflect
the reported higher levels of phosphorylated JNK2 de-
tected in the ME after bacterial inoculation, when com-
pared to JNK1 [23].
The fact that JNK1-deficient mice exhibit enhanced
neutrophil recruitment and epithelial thickness early in
OM could reflect a role for this isoform in limiting in-
flammation during early OM. Supporting this possibility,
JNK1 has been found to be protective against ischemic
injury in the brain [40].Implications and limitations of the study
Drawing conclusions from animal studies regarding hu-
man disease must, of course, be performed with caution.
Although the characteristics of NTHi-induced OM in
mice are quite similar to those observed in humans (e.g.
[3,29]), differences in genetics and in the response of
mice to a human pathogen must be considered in the in-
terpretation of data. With this caveat, our findings have
implications for the treatment of OM. The use of JNK
inhibitors alone to treat OM would probably not be ad-
visable, given the possibility of reduced bacterial clear-
ance. However, our data suggest that, in combination
with antibiotics, JNK inhibition has the potential to re-
duce inflammation and mucosal hyperplasia. Any such
strategy would need to take into account differences the
roles of JNK1 and JNK2 in OM. Thus, a JNK2-specific
inhibitor might be more beneficial than a pan-JNK
inhibitor.
Conclusions
In summary, we found that JNK signaling plays a signifi-
cant role in OM, as reflected by altered expression of
JNK signaling genes, as well as reduced bacterial clear-
ance and altered ME phenotype in mice deficient in JNK
isoforms. JNK1 and JNK2 are both required for the nor-
mal resolution of NTHi infection in the ME. JNK1 and
JNK2 appear to play both redundant and distinct roles
in OM, with JNK2 mediating the early recruitment of
neutrophils and being more critical for bacterial clear-
ance. JNK1 may actually limit inflammation early in
OM. The results have implications for JNK inhibition as
a therapeutic option in OM.
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